Theravance Biopharma Inc (NAS:TBPH)
$ 9.85 0.46 (4.9%) Market Cap: 479.04 Mil Enterprise Value: 399.84 Mil PE Ratio: 0 PB Ratio: 2.33 GF Score: 47/100

Q2 2023 Theravance Biopharma Inc Earnings Call Transcript

Aug 07, 2023 / 09:00PM GMT
Release Date Price: $9.83 (-1.21%)
Operator

Ladies and gentlemen, good afternoon. I'd like to welcome everyone to Theravance Biopharma's Second Quarter 2023 Conference Call. (Operator Instructions)

Also, today's conference call is being recorded. And now I'd like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir.

Rick E. Winningham
Theravance Biopharma, Inc. - Chairman & CEO

Good afternoon, and thank you for joining the Theravance Biopharma's Second Quarter 2023 Conference Call. On Slide 2, I'd remind you that this call will contain forward-looking statements that involve risks and uncertainties and the statements about our development pipeline, expected benefits of our products, anticipated timing of clinical trials, regulatory filings and expected financial results. Information concerning factors that could cause results to differ materially from our forward-looking statements is described further in our filings with the SEC.

Turning your attention to Slide 3. I'm joined today by Rhonda Farnum, Chief Business Officer; Rick Graham, Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot